- Active not recruitingPHASE3
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study looks at a medicine called ritlecitinib for non-segmental vitiligo, a skin condition causing white patches. It checks how safe and effective the medicine is and if it keeps working or helps more. People who were in an earlier study can join this one.
For: VitiligoUnited States · Australia · Bulgaria - Active not recruitingPHASE3
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
This study looks at a new medicine called ritlecitinib for people with vitiligo. It wants to see if this medicine can safely and effectively help treat the white patches on the skin caused by vitiligo. It's for adults aged 18 and over.
For: Stable Nonsegmental Vitiligo · Active Nonsegmental VitiligoUnited States · Australia · Belgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
B7981078: A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PEDIATRIC RITLECITINIB (PF-06651600) SPRINKLED IN APPLESAUCE, YOGHURT AND STRAWBERRY JAM RELATIVE TO INTACT BLEND-IN CAPSULE OF RITLECITINIB AND THE EFFECT OF FOOD ON THE BIOAVAILABILITY OF THE CAPSULE DOSAGE FORMULATION OF RITLECITNIB IN HEALTHY ADULT PARTICIPANTS
This study is looking at a new medicine called ritlecitinib. We're checking how well your body absorbs it when mixed with applesauce, yoghurt, or jam, compared to taking it as a capsule. We're also seeing if food changes how well the capsule works.
For: Alopecia Areata · Rheumatoid Arthritis · VitiligoBelgium - Recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
This study looks at how well a new medicine called Ritlecitinib works for people with a type of hair loss called alopecia areata in everyday life. It will check patient details, how the medicine is used, and how patients feel about their treatment.
For: Alopecia AreataUnited States · China · France - AuthorisedTherapeutic confirmatory (Phase III)
B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
This study is looking long-term at a medicine called ritlecitinib for severe alopecia areata, a condition causing hair loss. It's checking how safe and effective the medicine is in people who were in earlier trials. The goal is to see if it helps with hair regrowth and overall well-being.
For: Alopecia areataItaly · France · Czechia